Agents that target cysteine residues of biomolecules and their therapeutic potential

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 5, 2001, Pages 765-787

  Scozzafava, A ^a   Mastrolorenzo, A ^a   Supuran, C T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anticancer agents; Antivirals; Cysteine; Disulfides; Dithiocarbamates; Farnesyl transferase inhibitor; Glutathione; H+ K+ ATP ase inhibitors; HIV; HPV; Pentafluorosulfonamides; Ras; S glutathione transferase; Sulfonamides; Thiols; Tubulin; Zinc fingers

Indexed keywords

AMINO ACID; ANGIOTENSIN RECEPTOR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARRIER PROTEIN; COLCHICINE; CYSTEINE; DISULFIDE; DISULFIRAM; GERANYLTRANSFERASE; GLYCOPROTEIN P; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; LONAFARNIB; METAL ION; OMEPRAZOLE; PANTOPRAZOLE; PROTEIN; PROTEIN FARNESYLTRANSFERASE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RAS PROTEIN; SULFONAMIDE; THIOL; TUBULIN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ZINC FINGER PROTEIN;

CHEMICAL REACTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG TARGETING; DRUG TOXICITY; ELECTRON; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; OXIDATION REDUCTION REACTION; PAPILLOMA; PEPTIC ULCER; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; WART VIRUS;

EID: 0035002898     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.5.765     Document Type: Review

References (92)

1. Native disulfide bond formation in proteins
2. Disulfide bonds and protein folding
3. Chemical strategies for the global analysis of protein function
4. The chemistry of S-nitrosothiols
5. Peroxynitrite modification of protein thiols: Oxidation, nitrosylation and S-glutathiolation of functionally important cysteine residue(s) in the sarcoplasmic reticulum of Ca-ATP-ase
6. Metallothionein III
7. Zinc proteins
8. Zinc and immunoresistance to infection in aging: New biological tools
9. Zinc, T-cell pathways, aging: The role of metallothioneins
10. Zinc, infections and immunosenescence
11. Zinc coordination, function and structure of zinc enzymes and other proteins
12. Carbonic anhydrase inhibitors and their therapeutic potential
13. Bacterial proteases: Current therapeutic use and future prospects for the development of new antibiotics
14. Metals
15. The origin of prokaryotic C2H2 zinc finger regulators
16. Zinc-dependent protein folding
17. Novel anticancer drug discovery
18. Cysteine proteases and their inhibitors
19. Antiretroviral therapy: State of the HAART
20. New trends in antiretroviral therapy of HIV infection
21. Antiretroviral therapy of HIV-1 infection: Established treatment strategies and new therapeutic options
22. Inhibition of HIV infectivity by zinc-ejecting C-nitroso compounds
23. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS
24. Investigation of zinc-binding affinities of Moloney murine leukemia virus nucleocapsid protein and related zinc finger and modified peptides
25. Structural investigation on the requirement of CCHH zinc finger type nucleocapsid protein of human immunodeficiency virus 1
26. Biophysical characterization of zinc ejection from HIV nucleocapsid protein by anti-HIV 2,2′-dithiobis[benzamides] and benzisothiazolones
27. A new class of anti-HIV agents targeted towards the nucleocapsid protein NCp7: The 2,2′-dithiobisbenzamides
28. Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc
29. Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers
30. Inactivation of HIV-1 nucleocapsid protein P7 by pyridinioalkanoyl thiolesters
31. Carbonic anhydrase inhibitors: Perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action
32. Carbonic anhydrase inhibitors: Water soluble 4-sulfamoylphenylthioureas as topical intraocular pressure lowering agents with long lasting effects
33. Metal-chelating inhibitors of a zinc finger protein HIV-EP1 remarkable potentiation of inhibitory activity by introduction of SH groups
34. Targeting the dimerization interface for irreversible inhibition of HIV-1 protease
35. Structural and biochemical studies of retroviral proteases
36. The catalytic activity of protein disulfide isomerase is involved in human immunodeficiency virus envelope-mediated membrane fusion after CD4 cell binding
37. New drug combination for the treatment of murine AIDS and macrophage protection
38. Treatment of papillomavirus gynecologic infections
39. Human papillomavirus oncogenesis
40. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals
41. Distinctive distribution of human papillomavirus Type 16 and Type 20 in the tonsillar and the skin carcinomas of a patient with epidermodysplasia verruciformis
42. Imiquimod: An immune response modifier
43. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton
44. Human papillomavirus Type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase
45. A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses
46. E6 protein of human papillomavirus Type 18 binds zinc
47. Potential drugs against cervical cancer: Zinc-ejecting inhibitors of human papillomavirus Type 16 E6 oncoprotein
48. Inactivation of the human papillomavirus-16 E6 oncoprotein by organic disulfides
49. Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation
50. Inhibition of human cytomegalovirus UL80 protease by specific intramolecular disulfide bond formation
51. 2-Chloro-3-substituted-1,4-naphthoquinone inactivators of human cytomegalovirus UL80 protease
52. Novel antineoplastic agents with efficacy against multidrug resistant tumor cells
53. Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells
54. Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors
55. Arylsulfonyl-N,N-diethyl-dithiocarbamates: A novel class of antitumor agents
56. Arylsulfonyl-N,N-dialkyl-dithiocarbamates as tumor cell growth inhibitors: Novel agents targeting β-tubulin?
57. Carbonic anhydrase inhibitors: Synthesis of N-morpholylthiocarbonyl sulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozyme I, II and IV
58. Carbonic anhydrase inhibitors. Sulfonamides as antitumor agents?
59. Ras - A molecular switch involved in tumor formation
60. Inhibitors of prenylation of Ras and other G-proteins and their applications as therapeutics
61. Inhibition of Ras-targeted prenylation: Protein farnesyl transferase inhibitors revisited
62. Farnesylation of nonpeptidic thiol compounds by protein farnesyltransferase
63. Enzymatic kinetic resolution of atropisomers: Synthesis of a key intermediate of the farnesyl protein transferase inhibitor SCH66336
64. Preparation and properties of arsonolipids containing liposomes
65. Carbonic anhydrase inhibitors. Part 33 Isozyme II inhibition with 2,3-dihydroxypropylarsonic acids and arsonolipids
66. Carbonic anhydrase inhibitors. Part 42 Carbonic anhydrase interaction with lipothioarsenites: A novel class of isozymes I and II inhibitors
67. Carbonic anhydrase inhibitors. Part 87 Inhibition of carbonic anhydrase isozymes I, II and IV with arsinolipids
68. Metabolism and functions of glutathione in brain
69. Glutathione conjugation as a bioactivation reaction
70. Mammalian class theta GST and differential susceptibility to carcinogenesis: A review
71. The non-enzymatic displacement of the sulfamoyl group from different classes of aromatic compounds by glutathione and cysteine
72. Cysteine conjugate of methazolamide is metabolized by β-lyase
73. Carbonic anhydrase inhibitors
74. Topically active carbonic anhydrase inhibitors. 1 O-Acyl derivatives of hydroxybenzothiazole-2-sulfonamide
75. +-activated oxidizing agent of sulfhydryls groups
76. +-ATP-ase
77. Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV
78. Carbonic anhydrase inhibitors. Novel compounds containing S-NH moieties in their molecule: Sulfenamido-sulfonamides, sulfenimido-sulfonamides and their interaction with isozymes I, II and IV
79. Crystal structure of S-glutathiolated carbonic anhydrase III
80. Formation of intersubunit disulfide bonds and properties of the single histidine and cysteine residues in each subunit relative to the decameric structure of cyanase
81. The fast-reacting sulfhydryl group of rat muscle phosphoglycerate kinase is necessary for activity and maintenance of tertiary structure
82. Thiol modifications of diacylglycerol kinase: Dependence upon site membrane disposition and reagent hydrophobicity
83. Inactivation of creatine kinase by S-glutathiolation of the active site cysteine residue
84. 2 angiotensin II receptor from cysteine-disulfide bond exchange
85. 56 residue with the SH reagent methyl methanethiosulfonate
86. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism
87. Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol modifications techniques
88. Effect of S-nitrosothiols on cellular glutathione and reactive protein sulfhydryls
89. Influence of glutathione on the oxidation chemistry of 5-S-cysteinyldopamine: Potentially neuroprotective reactions of relevance to Parkinson's disease
90. Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole in HIV infection
91. Oral N-acetylcysteine increases the production of anti-HIV chemokines in peripheral blood mononuclear cells
92. Synthesis, incorporation efficiency and stability of disulfide bridged functional groups at RNA 5′-ends